Getting in on the Embolic Protection Action for TAVR

There has been an increase in the need for embolization protection devices as the risk for stroke and other neurological damage from transcatheter aortic valve replacement (TAVR) procedures continues to become more prevalent.   Santa Cruz, CA -based Emboline is looking to enter the embolization protection space, which is set to grow from $406 million this year to $605 million by 2023, according to a report from ResearchandMarkets. The emerging medtech company's contribution to the space would come from its Emboliner Embolic Protection Catheter.  The Emboliner is a cylindrical mesh filter that completely lines the aorta. The design allows the device to have more reliable positioning across the cerebral vessels and is simple to put in, the company said. Recently, the small firm said it has raised $10 million in a Series B round to help get the technology to the market. The funding includes $3 million in new equity financing from multiple investors led by SV Tech Ventures and Shangbay Capital, and more than $7 million in conversion of previously-issued convertible notes. “The purpose of the [Series B] round is to fund completion of our first human clinical study,” Scott Russell, president and CEO of Emboline, told MD+DI. “The data from that clinical study will be used to file for CE mark. We’re expecting the trial to be complete and the CE mark filing to be done at the end of this year. So, our hope is to launch commercially in Europe by the end of the year.” Fo...
Source: MDDI - Category: Medical Devices Authors: Tags: Implants Cardiovascular Source Type: news